Literature DB >> 8696952

Urinary excretion of apo(a) fragments. Role in apo(a) catabolism.

K M Kostner1, G Maurer, K Huber, T Stefenelli, H Dieplinger, E Steyrer, G M Kostner.   

Abstract

The biosynthesis and assembly of lipoprotein(a) [Lp(a)], a marker for atherosclerotic disease, appears to be well understood. However, information is lacking concerning the mode and site of Lp(a) catabolism. Apo(a) is reported to be excreted into the urine. To study the effect of this pathway on the overall catabolism of Lp(a), urinary apo(a) was characterized by immunoblotting. More than 10 distinct apo(a) bands with molecular masses between 30 and 160 kD were observed. Apo(a) fragments were not complexed to apoB. In more than 30 individuals the size of apo(a) bands was comparable irrespective of their apo(a) phenotype, although marked differences in the relative intensities of the bands were observed. Eight batches of 24-hour urine collections collected from one proband at 2-week intervals exhibited a significant correlation between creatinine and apo(a) concentrations as measured by DELFIA (r = .93; P < .01). In 193 healthy volunteers a highly significant correlation was found between urinary apo(a) concentrations normalized to creatinine levels and plasma Lp(a) values (p = 0.659; P < .0001). Of the total plasma apo(a), 0.073%, i.e., 121 micrograms apo(a), was excreted in the form of apo(a) fragments in 24-hour urine samples from 12 healthy volunteers. We conclude that the catabolism of Lp(a) via excretion of apo(a) fragments accounts for < 1% of the daily Lp(a) catabolism.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8696952     DOI: 10.1161/01.atv.16.8.905

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  13 in total

1.  Galactose-specific asialoglycoprotein receptor is involved in lipoprotein (a) catabolism.

Authors:  Andelko Hrzenjak; Sasa Frank; Xingde Wo; Yonggang Zhou; Theo Van Berkel; Gert M Kostner
Journal:  Biochem J       Date:  2003-12-15       Impact factor: 3.857

Review 2.  Causes and consequences of lipoprotein(a) abnormalities in kidney disease.

Authors:  Florian Kronenberg
Journal:  Clin Exp Nephrol       Date:  2013-10-16       Impact factor: 2.801

Review 3.  Lipoprotein (a): a historical appraisal.

Authors:  Karam M Kostner; Gert M Kostner
Journal:  J Lipid Res       Date:  2016-11-07       Impact factor: 5.922

Review 4.  Structure, function, and genetics of lipoprotein (a).

Authors:  Konrad Schmidt; Asma Noureen; Florian Kronenberg; Gerd Utermann
Journal:  J Lipid Res       Date:  2016-04-13       Impact factor: 5.922

Review 5.  Lipoprotein(a) metabolism: potential sites for therapeutic targets.

Authors:  Jane Hoover-Plow; Menggui Huang
Journal:  Metabolism       Date:  2012-10-04       Impact factor: 8.694

6.  Lipoprotein(a): biology and clinical importance.

Authors:  Sally P A McCormick
Journal:  Clin Biochem Rev       Date:  2004-02

7.  Dyslipidemia associated with chronic kidney disease.

Authors:  Vasilis Tsimihodimos; Zoi Mitrogianni; Moses Elisaf
Journal:  Open Cardiovasc Med J       Date:  2011-02-24

Review 8.  The metabolism of lipoprotein (a): an ever-evolving story.

Authors:  Gissette Reyes-Soffer; Henry N Ginsberg; Rajasekhar Ramakrishnan
Journal:  J Lipid Res       Date:  2017-07-18       Impact factor: 5.922

9.  Apolipoprotein(a) inhibits in vitro tube formation in endothelial cells: identification of roles for Kringle V and the plasminogen activation system.

Authors:  Lei Liu; Michael B Boffa; Marlys L Koschinsky
Journal:  PLoS One       Date:  2013-01-11       Impact factor: 3.240

Review 10.  Lipoprotein(a) in cardiovascular diseases.

Authors:  Michele Malaguarnera; Marco Vacante; Cristina Russo; Giulia Malaguarnera; Tijana Antic; Lucia Malaguarnera; Rita Bella; Giovanni Pennisi; Fabio Galvano; Alessandro Frigiola
Journal:  Biomed Res Int       Date:  2012-12-30       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.